Filters
Hikma completes Xellia acquisition
Press Release, Corporate 10 September 2024
Hikma launches Clindamycin in 5% Dextrose Injection in the US
Press Release, Product 03 September 2024
New
Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA
Insight, Corporate 28 August 2024
New
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fenta...
Press Release, Product 20 August 2024
New
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
Press Release, Product 15 August 2024
Hikma delivers strong H1 performance and upgrades Group guidance
Press Release, Financial Results 08 August 2024
New
Hikma Pharmaceuticals: how our three businesses work together to improve health
Insight, Corporate 31 July 2024
New
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, ...
Press Release, Product 22 July 2024
New
Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers ...
Press Release, Product 16 July 2024
Hikma launches Sodium Acetate Injection, USP, in the US
Press Release, Product 11 July 2024
New
Hikma – A legacy of quality for a better future
Insight, Corporate 24 June 2024
Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D
Press Release, Corporate 17 June 2024
Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House mee...
Press Release, Corporate 06 June 2024
Hikma opens new UK office to support NHS supply, strengthening European presence
Press Release, Corporate 03 June 2024
You have viewed 15 of 441 results